Table 9 shows a statistical comparison of the findings from the examination of Martibendazene® oral suspension using the suggested HPLC and TLC procedures with the methods that have been previously described
Parameters | Levamisole | Triclabendazole | ||||
|---|---|---|---|---|---|---|
Proposed HPLC method | Proposed TLC method | Reported Method [75] | Proposed HPLC method | Proposed TLC method | Reported Method [60] | |
N* | 5 | 5 | 5 | 5 | 5 | 5 |
X̅** | 100.74 | 99.87 | 99.77 | 100.46 | 99.76 | 100.66 |
SD | 0.924 | 0.951 | 0.938 | 0.961 | 0.493 | 0.856 |
Variance | 0.854 | 0.905 | 0.879 | 0.925 | 0.243 | 0.733 |
Student’s-t-test*** | 1.647 (2.306) | 0.175 (2.306) | ___ | 0.360 (2.306) | 2.045 (2.306) | ___ |
F-value *** | 1.029 (6.388) | 1.029 (6.388) | ___ | 1.262 (6.388) | 3.016 (6.388) | ___ |